Rodolphe Barrangou Ph.D. is the T. R. Klaenhammer Distinguished Professor at North Carolina State University. Barrangou is focusing on the characterization of CRISPR-Cas systems, and their applications in bacteria. The CRISPRlab has published numerous studies on the various applications of CRISPR-Cas systems, and illustrated their use for the study and development of probiotics, including for genotyping, phage resistance, screening, genome editing and antimicrobials, to understand and enhance health-promoting functions of interest. The work has spanned basic scientific to understand and decipher the genomics of lactic acid bacteria, as well as developing novel technologies and applying them to develop and formulate next-generation bacterial strains. Rodolphe spent 9 years in R&D and M&A at Danisco and DuPont, and has been at NC State since 2013. For his CRISPR work, Rodolphe received several international awards, including the 2016 Canada Gairdner International Award, the 2016 Harvard Medical School Warren Alpert Prize, the 2017 NAS Award in Molecular Biology and the 2018 NAS Prize in Food and Agriculture Sciences. He has been elected into the National Academy of Sciences, the National Academy of Engineering, the National Academy of Inventors, the American Academy of Microbiology and the National Inventors Hall of Fame. Dr. Barrangou earned a BS in Biological Sciences from Rene Descartes University in Paris, France, a MS in Biological Engineering from the University of Technology in Compiegne, France, a MS in Food Science from NC State, a PhD in Genomics from NC State and a MBA from the University of Wisconsin-Madison. Dr. Barrangou is also the former Chairman of the Board of Caribou Biosciences (NASDAQ CRBU), a co-founder of Intellia Therapeutics (NASDAQ NTLA), Locus Biosciences, TreeCo, Ancilia Biosciences and CRISPR Biotechnologies, an advisor to Inari Ag, Invaio, Provaxus and Felix Biotech, and the Editor in Chief of the CRISPR Journal.